PT Phapros TbkISX:PEHA +0.78%74 Net Margin % is 0.69% as of Mar. 2026, which is 83% below its 10-year median of 3.96. GuruFocus rates ISX:PEHA with a GF Score™ of 74/100 and a GF Value™ of Rp385.70 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 956 Drug Manufacturers companies, PT Phapros Tbk ranks worse than 55.96% on this metric.
Net margin is calculated as Net Income divided by its Revenue. PT Phapros Tbk's Net Income for the
three
months ended in Mar. 2026 was Rp1,532 Mil. PT Phapros Tbk's Revenue for the
three
months ended in Mar. 2026 was Rp221,088 Mil. Therefore, PT Phapros Tbk's net margin for the quarter that ended in Mar. 2026 was 0.69%.
The historical rank and industry rank for PT Phapros Tbk's Net Margin % or its related term are showing as below:
ISX:PEHA'
s Net Margin % Range Over the Past 10 Years
Min: -38.28 Med: 3.96 Max: 12.93
Current: 3.67
ISX:PEHA's Net Margin % is ranked worse than 55.96% of 956
companies
in the Drug Manufacturers industry
Industry Median: 5.56
vs ISX:PEHA: 3.67
PT Phapros Tbk (ISX:PEHA) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
PT Phapros Tbk Net Margin % Related Terms
PT Phapros Tbk Net Margin % Historical Data
* Premium members only.
The historical data trend for PT Phapros Tbk's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ISX:PEHA vs ZTS, UTHR, VTRS: Net Margin % Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PT Phapros Tbk's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Phapros Tbk Net Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PT Phapros Tbk's Net Margin % distribution charts can be found below:
* The bar in red indicates where PT Phapros Tbk's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Phapros Tbk (ISX:PEHA) has a Net Margin % of 0.69% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on PT Phapros Tbk and its competitors. This is 83% below median its historical median of 3.96. According to the industry distribution chart, PT Phapros Tbk ranks #535 out of 956 companies in the Drug Manufacturers industry, placing it in the top 56%.
Is PT Phapros Tbk's Net Margin % too high?
PT Phapros Tbk's current Net Margin % of 0.69% is 83% below median its 10-year median of 3.96. The Drug Manufacturers industry median Net Margin % is 5.56. PT Phapros Tbk's value of 0.69% is 87.6% below this industry median. Based on the distribution chart, PT Phapros Tbk ranks #535 out of 956 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, PT Phapros Tbk has a GF Score™ of 74/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does PT Phapros Tbk's Net Margin % compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PT Phapros Tbk ranks #535 out of 956 companies for Net Margin %. This places PT Phapros Tbk in the lower half of its industry. The industry median Net Margin % is 5.56. PT Phapros Tbk's value of 0.69% is 87.6% below this benchmark. While the company's 10-year median is 3.96 vs. the industry median of 5.56, PT Phapros Tbk has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Drug Manufacturers company?
The median Net Margin % among Drug Manufacturers companies is 5.56, based on 956 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PT Phapros Tbk's current Net Margin % of 0.69% is 87.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on PT Phapros Tbk and its competitors. For the Drug Manufacturers industry, the median Net Margin % is 5.56 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PT Phapros Tbk's current Net Margin % is 0.69%, which is 83% below median its own 10-year median of 3.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Phapros Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Phapros Tbk (ISX:PEHA) is currently considered Possible Value Trap. The stock's GF Value™ is Rp385.70, compared to a current price of Rp260.00 — trading 32.6% below its estimated fair value. The current Net Margin % is 0.69%, which is 83% below median its 10-year median of 3.96 and 87.6% below the Drug Manufacturers industry median of 5.56. PT Phapros Tbk's overall GF Score™ is 74/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For PT Phapros Tbk (ISX:PEHA), the current Net Margin % is 0.69% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Phapros Tbk (ISX:PEHA) Overvalued in 2026?
Based on GuruFocus' analysis, PT Phapros Tbk stock appears to be undervalued.
The current stock price of Rp260.00 is trading 32.6% below its estimated GF Value™ of Rp385.70.
GuruFocus considers PT Phapros Tbk to be Possible Value Trap.
Key valuation signals for ISX:PEHA:
Net Margin %: 0.69% (83% below median its 10-year median of 3.96)
GF Value™: Rp385.70 vs. price of Rp260.00 (32.6% below fair value)
Industry Position: 87.6% below the Drug Manufacturers median (#535 of 956)
No single metric tells the full story. See the ISX:PEHA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Phapros Tbk is a pharmaceutical company in Indonesia. The company is engaged in the industrial/manufacturing sector by producing and/or trading medicines, health instruments, chemical goods, and other similar goods in import, export, and other kinds of industry. The company operates through Over Counter (OTC), Ethical, Generic Drugs Bearing (OGB), and Toll Manufacturing segments. It derives maximum revenue from OGB segment.
74GF Score
Get the complete analysis for ISX:PEHA
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:PEHA has been successfully added to your 
